XSpray Pharma AB (OSTO:XSPRAY) GF Score: 29/100 (As of Aug. 03, 2026) — 16% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XSPRAY XSpray Pharma AB OSTO:XSPRAY
29 GF Score
Price kr16.88
! 1 Warning Sign
View Full Analysis

What is XSpray Pharma AB GF Score?

XSpray Pharma AB OSTO:XSPRAY +1.44% 29 GF Score is 29 as of Aug. 03, 2026, which is 16% above its 10-year median of 25.00. GuruFocus rates OSTO:XSPRAY with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

XSpray Pharma AB has the GF Score of 29, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes XSpray Pharma AB might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

XSpray Pharma AB  (OSTO:XSPRAY) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

XSpray Pharma AB GF Score Related Terms

OSTO:XSPRAY vs VRTX, REGN, RVMD: GF Score Comparison

For the Biotechnology subindustry, XSpray Pharma AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XSpray Pharma AB GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's GF Score distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's GF Score falls into.


OSTO:XSPRAY
29GF Score
XSpray Pharma AB OSTO:XSPRAY
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 29 mean?
XSpray Pharma AB (OSTO:XSPRAY) has a GF Score of 29 as of Aug. 03, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on XSpray Pharma AB and its competitors. This is 16% above median its historical median of 25.00. Over the past decade, XSpray Pharma AB's GF Score has ranged from 6.00 to 40.00.
Is XSpray Pharma AB's GF Score too high?
XSpray Pharma AB's current GF Score of 29 is 16% above median its 10-year median of 25.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 40.00. Overall, XSpray Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's GF Score compare to VRTX and REGN?
XSpray Pharma AB's GF Score of 29 can be compared against companies in the Biotechnology industry. Historically, XSpray Pharma AB's own GF Score has ranged from 6.00 to 40.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on XSpray Pharma AB and its competitors. XSpray Pharma AB's current GF Score is 29, which is 16% above median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (OSTO:XSPRAY) has a current GF Score of 29. The current GF Score is 29, which is 16% above median its 10-year median of 25.00. XSpray Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For XSpray Pharma AB (OSTO:XSPRAY), the current GF Score is 29 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XSpray Pharma AB Business Description

Other Exchanges 0GHZ:UK6XP:Germany
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
29GF Score

Get the complete analysis for OSTO:XSPRAY

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr16.88
Price